(ET-1) plays an important role in the regulation of salt and water excretion in the kidney. Considerable in vitro evidence suggests that the renal medullary ET B receptor mediates ET-1-induced inhibition of electrolyte reabsorption by stimulating nitric oxide (NO) production. The present study was conducted to test the hypothesis that NO synthase 1 (NOS1) and protein kinase G (PKG) mediate the diuretic and natriuretic effects of ETB receptor stimulation in vivo. Infusion of the ETB receptor agonist sarafotoxin S6c (S6c: 0.45 g ⅐ kg Ϫ1 ⅐ h Ϫ1 ) in the renal medulla of anesthetized, male Sprague-Dawley rats markedly increased the urine flow (UV) and urinary sodium excretion (UNaV) by 67 and 120%, respectively. This was associated with an increase in medullary cGMP content but did not affect blood pressure. In addition, S6c-induced diuretic and natriuretic responses were absent in ETB receptor-deficient rats.
G
-propyl-L-arginine (10 g⅐kg Ϫ1 ⅐h
Ϫ1
), a selective NOS1 inhibitor, suppressed S6c-induced increases in UV, UNaV, and medullary cGMP concentrations. Rp-8-Br-PET-cGMPS (10 g ⅐ kg Ϫ1 ⅐ h Ϫ1 ) or RQIKIWFQNRRMKWKK-LRK5H-amide (18 g ⅐ kg Ϫ1 ⅐ h Ϫ1 ), a PKG inhibitor, also inhibited S6c-induced increases in UV and UNaV. These results demonstrate that renal medullary ET B receptor activation induces diuretic and natriuretic responses through a NOS1, cGMP, and PKG pathway. sodium excretion; nitric oxide synthase 1; guanosine 3Ј,5Ј-cyclic monophosphate; protein kinase G ENDOTHELIN-1 (ET-1), originally described as being released from vascular endothelial cells (46) , is now known to be produced by many cell types and exerts a variety of biological effects in various organ systems (27) . The renal medulla is a major site of ET-1 synthesis in the body (14, 42) . Considerable evidence has accumulated in recent years to demonstrate the physiological importance of renal medullary ET-1 in the control of arterial pressure and salt sensitivity. In inner medullary collecting duct (IMCD) cells, ET-1 reduced ouabain-sensitive Na-K-ATPase (47) and amiloride-sensitive sodium channel (6) activities. Furthermore, ET-1 inhibits chloride flux in isolated thick ascending limbs, an effect blocked by an ET B , but not ET A , antagonist (22) . These in vitro studies suggest that activation of the renal medullary ET B receptors by ET-1 could play an important role in the regulation of salt and water excretion. Indeed, rats or mice lacking functional ET B receptors display salt-sensitive hypertension (2, 7) . Early studies showed that low-dose infusion of ET-1 could produce a direct natriuretic and diuretic effect in vivo without any associated changes in blood pressure (28) . A more definitive study demonstrating the physiological significance of renal ET-1 in control of sodium excretion comes from the observation that mice lacking specific expression of ET-1 within the renal collecting duct develop hypertension that is salt dependent (1) .
Nitric oxide (NO) is thought to act as the downstream mediator of renal ET B receptor activation, because total NO synthase (NOS) inhibition can inhibit ET B receptor-dependent responses both in vivo (17) and in vitro (22) . However, which NOS isoform is mainly involved in ET B -mediated diuretic and natriuretic responses remains unclear because all three NOS isoforms are expressed in tubules within the renal medulla (18, 33) . Previous studies have demonstrated that NOS1 contributes to roughly 40% of basal NO production in the renal medulla (12) . Inhibition of renal medullary NOS1 by intrarenal infusion of antisense oligonucleotides or specific enzyme inhibitors elevated the blood pressure in rats fed a high-salt diet (19) , thus indicating the importance of medullary NOS1 on control of sodium balance. Moreover, Stricklett et al. (35) have shown that ET-1 stimulated both NO and cGMP production in rat IMCD cells and that an ET B receptor antagonist or NOS1 selective inhibitor suppressed this increase in NO production. In addition, feeding rats a high-salt diet, which is known to increase renal ET-1 production (29), has been reported to increase the expression of NOS1 protein in the IMCD (26) , although this has not been a consistent finding (36) . Taken together, these observations led us to hypothesize that ET B receptors within the renal medulla produce a diuretic and natriuretic effect by activation of NOS1 as a means of facilitating salt excretion in vivo. Thus we determined the effect of renal medullary infusion of an ET B receptor selective agonist, sarafotoxin 6c (S6c), on urine sodium and water excretion in normotensive rats. Furthermore, we examined whether NOS1, cGMP, and/or protein kinase G (PKG) could be effectors of the downstream signaling events during ET B receptor-dependent responses.
METHODS

Materials
S6c was obtained from American Peptide (Sunnyvale, CA). N Gpropyl-L-arginine (NPA), Rp-8-Br-PET-cGMPS (Rp-cGMP), and BSA were purchased from Calbiochem (La Jolla, CA). PKG inhibitor peptide RQIKIWFQNRRMKWKK-LRK 5H-amide (DT-3) was purchased from Axxora (Bingham, UK). All other reagents were obtained from Sigma Chemical (St. Louis, MO).
Animals
Experiments used male Sprague-Dawley (SD) rats (250 -350 g) from Harlan Laboratories (Indianapolis, IN). Additional experiments used male wild-type (control) and homozygous (sl/sl) rats deficient of ET B receptors (Wistar genetic background) obtained from our local breeding colony. Both control and sl/sl rats carry the transgene for dopamine-␤-hydroxylase that rescues the ET B-deficient rats from a lethal phenotype by expressing a functional ETB receptor in adrenergic tissues (7, 37) . The Medical College of Georgia Institutional Animal Care and Use Committee approved experimental protocols and animal care procedures in all experiments.
Surgical Preparation
Rats were anesthetized with inactin (100 mg/kg ip) and placed on a servo-controlled heating table to maintain rectal temperature constant at 37°C. The trachea was cannulated (PE-205) to facilitate respiration. The right femoral artery was catheterized for monitoring blood pressure using a MacLab data acquisition system (AD Instruments, Milford, MA), and the right jugular vein was catheterized for infusion of PBS (0.9% NaCl) containing 6.2% BSA at a rate of 1.8 ml/h to maintain euvolemia. A midline incision was made, and a stretched PE-10 catheter was inserted 5 mm in the left kidney and secured to the renal capsule. After the catheter was inserted, saline (0.9% NaCl) was infused directly in the renal medulla at 0.5 ml/h. Medullary blood flow was measured by single-fiber, laser Doppler flowmetry as previously described (39) . Urine was collected separately from the left and right kidneys via catheters placed in each ureter. Experiments were started after an 80-min equilibration period. At the end of each experiment, the kidneys were dissected to ensure the catheter was in the appropriate position within the medulla. Protocol 1. After two 20-min control urine collection periods, increasing doses of S6c (0.15, 0.45 and 1.5 g ⅐ kg Ϫ1 ⅐ h Ϫ1 ) were infused in the renal medullary interstitium of SD rats for two 20-min experimental periods at each dose. A separate group of rats received an infusion of saline vehicle during control and experimental periods.
Protocol 2. Again, following two 20-min control periods, increasing doses of S6c (0.15 and 0.45 g ⅐ kg Ϫ1 ⅐ h Ϫ1 ) were infused in the renal medullary interstitium of ETB-deficient or control rats for two 20-min experimental periods at each dose.
Protocol 3. Following control periods, increasing doses of S6c (0.15 and 0.45 g ⅐ kg Ϫ1 ⅐ h Ϫ1 ) were infused in the renal medullary interstitium of SD rats. In additional groups of rats, the NOS1 inhibitor NPA (10 g ⅐ kg (5) was infused in the renal medulla beginning 40 min before S6c and was continued during S6c infusion.
Protocol 4. Following control periods, increasing doses of NPA (10 and 100 g ⅐ kg Ϫ1 ⅐ h Ϫ1 ) were infused in the renal medullary interstitium of SD rats for two 20-min experimental periods at each dose. After NPA infusion, the drug was changed to N G -nitro-L-arginine methyl ester (L-NAME; 100 g ⅐ kg Ϫ1 ⅐ h Ϫ1 ). The left renal medulla was dissected at the end of the infusion periods in the saline, S6c, and S6c ϩ NPA groups and was immediately frozen in liquid nitrogen for cGMP measurement. Samples were stored at Ϫ80°C until analysis.
Measurement of Medullary cGMP Content
cGMP was extracted from the tissue according to the protocol of Brophy et al. (3) . The medullas were homogenized in 500 l of ice-cold 10% TCA using a glass-Teflon homogenizer. The homogenate was centrifuged 15,000 g for 15 min at 4°C. The supernatant was washed four times with 5 vol of water-saturated ether, and the upper phase was discarded with each wash. The aqueous extract was dried using a vacuum evaporator (Jouan, Winchester, VA). The dried extract was reconstituted in 125 l of acetate buffer (50 mM, pH 6.2) and was saved for measurement of cGMP content by RIA (30) . The pellet was resuspended in 500 l of 1 N NaOH, and protein concentrations were determined by standard Bradford assay (Bio-Rad Laboratories, Hercules, CA) using BSA as the standard.
Statistical Analysis
All values were expressed as means Ϯ SE. For statistical analysis, we used one-way ANOVA followed by Tukey-Kramer multiplecomparison tests. Differences were considered significant at P Ͻ 0.05.
RESULTS
Renal medullary infusion of S6c dose-dependently increased both the urine flow and sodium excretion from the left kidney compared with infusion of saline (Fig. 1) . Urine flow and sodium excretion from the right kidney was increased when the highest dose of 1.50 g⅐kg Ϫ1 ⅐h Ϫ1 of S6c was infused in the left renal medulla, possibly through a renorenal reflex or spillover from the medullary infusion in the systemic circulation. Because of this effect in contralateral kidney, we used lower doses (0.15 and 0.45 g⅐kg Ϫ1 ⅐min Ϫ1 ) in the following experiments. Mean arterial pressure was not significantly affected by S6c infusion.
To further assess the specific role of ET B receptors in the excretory response to intramedullary infusion of S6c, we conducted similar experiments in ET B -deficient rats and their genetic controls (Fig. 2) . Medullary infusion of S6c induced a significant diuretic and natriuretic response in control rats that was not evident in ET B -deficient rats.
To estimate the involvement of NOS1 on ET B receptordependent diuretic and natriuretic responses, we determined the effects of treatment with NPA, a selective NOS1 inhibitor, on the response to S6c (Fig. 3) . Intramedullary infusion of NPA markedly suppressed the S6c-induced diuretic and natriuretic responses. Infusion of NPA without S6c had no effect on sodium or water excretion at the dose that inhibited the S6c response. No significant change was observed in urine flow or sodium excretion from the right kidney in any group. Likewise, mean arterial pressure was not changed in any group.
Because cGMP is a well-established second messenger of NO, we determined renal medullary cGMP content in animals given intramedullary infusion of saline, S6c, and S6c plus NPA (Fig. 4) . The left renal medulla of the S6c-infused group had a significantly greater amount of cGMP compared with the saline-infused group. NPA treatment completely suppressed the S6c-induced increase in cGMP content in renal medulla.
We further estimated the involvement of cGMP on S6c-induced diuretic and natriuretic responses by using the PKG inhibitor Rp-cGMP or DT-3 (Fig. 5) . Coinfusion of PKG inhibitor with S6c significantly inhibited the S6c-induced increase in urine flow and sodium excretion from the left kidney. The infusion of Rp-cGMP alone, but not DT-3, slightly but significantly increased the sodium excretion during 80 -120 min after the start of the infusion (data not shown). Urine flow rate and sodium excretion from the right kidney were unaffected by each PKG inhibitor infusion in the left kidney. No significant changes in mean arterial pressure were observed in any group.
Although NPA has high selectivity for the NOS1 in vitro, the selectivity in vivo has not been clarified yet. Therefore, to estimate the selectivity of NPA in vivo, we measured the changes in renal medullary blood flow in response to NPA or L-NAME, a nonselective NOS inhibitor (Fig. 6) . The medullary blood flow was unaffected by infusion of NPA, even at 100 g⅐kg Ϫ1 ⅐h Ϫ1 ; a dose 10 times higher than necessary inhibit the S6c-induced natriuresis. Subsequent infusion of L-NAME significantly decreased the medullary blood flow.
DISCUSSION
The evidence that ET-1 functions as a physiological regulator of renal sodium and water excretion has been slowly accumulating since the first identification of intrarenal ET-1 production along with a high concentration of ET B receptors within the renal medulla (24) . Our studies demonstrate that direct intramedullary stimulation of ET B receptors results in a diuretic and natriuretic response, which agrees with considerable in vitro data that ET B receptor stimulation inhibits renal tubular reabsorption (6, 22, 38) . Furthermore, we report that renal ET B -dependent increases in sodium and water excretion depend on the activity of NOS1 and appear to also function via cGMP stimulation of PKG.
Early studies examining the effect of systemically administered ET-1 did not agree on whether ET-1 increased or decreased urine flow and sodium excretion due to increases in arterial pressure or decreases in the filtered load of sodium (32) . Our studies employed the interstitial infusion technique (19) to minimize effects of ET receptor activation on renal perfusion pressure or glomerular filtration rate. Because we did not observe any changes in mean arterial pressure during intramedullary infusion of S6c, we can eliminate the possibility that the increase in urine sodium and water excretion was due to changes in renal perfusion pressure.
We also used the highly selective ET B agonist S6c to focus on ET B receptor-specific effects (43) . ET B receptors appear to be the predominant receptor subtype that accounts for the ability of ET-1 to inhibit sodium reabsorption (6, 22) . It has been established for many years that ET B receptors in the vascular endothelium stimulate NO production (11, 40) . Furthermore, the ability of the ET B receptor to reduce renal tubular transport has been attributed to increasing NO (22) . Matsuo and colleagues (17) have also reported that S6c infusion in the renal artery of anesthetized dogs results in a natriuretic and diuretic effect that is also associated with increases in urinary excretion of NO metabolites, nitrate and nitrite. A lingering question has been which NOS isoform could be involved in the proexcretory effects of ET B receptor stimulation. Herrera and Garvin (10) have shown that ET B receptor stimulation is responsible for increases in NOS3 expression in the thick ascending limb. This same laboratory has shown that NOdependent inhibition of chloride reabsorption involves NOS3
and not NOS1 (23) . In cultured collecting duct cells, however, Stricklett et al. (35) showed that ET-1 increases NO production via NOS1 activation, but not NOS2 or NOS3. Although all three NOS isoforms are expressed in both the thick ascending limb and the collecting duct, microdissection experiments suggest that the greatest amount of constitutive NOS activity is within the medullary collecting duct system (45), the same location as the greatest amount of ET-1 synthesis and ET B receptor expression (13, 15) . Therefore, it is tempting to speculate that the natriuretic and diuretic response to S6c observed in our experiments using intramedullary infusion is related to activity within the collecting duct although this idea awaits further clarification.
A number of studies have shown that the ET B receptor system can produce vasodilation within the renal microcirculation, and in particular, within the renal medulla (9, 31, 39) . Although increasing blood flow within the renal medullary circulation may contribute to reduced renal salt and water reabsorption, one could assume that ET B -mediated vasodilation would utilize the endothelial isoform, NOS3, and not NOS1, since ET B -mediated vasodilation is endothelial-dependent and there have been no reports of NOS1 expression in endothelial cells. Kakoki et al. (12) have shown that intravenous infusion of a selective NOS1 inhibitor does not influence medullary blood flow despite the fact that medullary NO levels were significantly decreased. This evidence is consistent with our result that shows intramedullary infusion of L-NAME but not NPA decreases the medullary blood flow. Again, this observation suggests that the ET B /NOS1 pathway is not through a hemodynamic mechanism. Therefore, our current findings of NOS1 dependency in the natriuretic response to S6c would suggest that a hemodynamic mechanism is unlikely and that the NOS1-dependent response to S6c is primarily due to an inhibitory effect on the tubular sodium reabsorption. Nonetheless, there remains the possibility that renal tubular NO production could contribute to hemodynamic effects within the renal medulla as suggested by Cowley and colleagues (4) .
An additional new finding in the present study is that the selective NOS 1 inhibitor NPA not only inhibited the diuretic and natriuretic actions of S6c but also inhibited S6c-induced increases in renal medullary cGMP content. These data agree with the hypothesis that ET B -dependent NO production inhibits renal tubular reabsorption through NOS1-dependent generation of NO and subsequent cGMP generation. Furthermore, participation of PKG appears likely, since the competitive inhibitor Rp-cGMP or DT-3 also inhibited the renal excretory response to S6c. cGMP has been known for many years to be an important factor in regulating renal tubular sodium reabsorption, especially in terms of the activity of factors such as atrial natriuretic peptide and guanylin (34, 48) .
A potential limitation to the present study is the selectivity of the pharmacological inhibitors in vivo. The selectivity of NPA for NOS1 is 150-and 3,200-fold greater than that of NOS3 and NOS2 in vitro (49) , but there have been no studies to clearly demonstrate selectivity of NPA for the NOS1 in vivo. We observed that doses of NPA that blocked the response to S6c (10 and 100 g⅐kg Ϫ1 ⅐min Ϫ1 ) had no effect on blood flow in the renal medulla (Fig. 6 ). However, a dose of the nonselective NOS inhibitor L-NAME (100 g⅐kg Ϫ1 ⅐min Ϫ1 ) produced a profound decrease in medullary blood flow consistent with inhibition of NOS3. The result indicates that NPA infusion does not appear to inhibit NOS3. In addition with this experiment, we attempted to confirm the involvement of NOS1 by using other NOS1 inhibitors, such as N 5 -(1-imino-3-butenyl)-ornithine or 7-nitroindazole. However, intramedullary infusion of these agents themselves induced strong diuretic responses (unpublished observations). In addition, even NPA increased the urine flow when we used the dosage higher than 100 g⅐kg Ϫ1 ⅐h Ϫ1 . The reasons for this apparent contradictory action of NOS1 revealed by administration of the other inhibitors and the higher dose of NPA is not known but may be due to spillover to inhibit cortical NOS1 in the macula densa to reduce tubuloglomerular feedback or effects on nerve activity. NOS1 was originally named neuronal NOS because it was first discovered in neuronal tissue and is known to play a critical role in modulating sympathetic nerve activity.
Mattson and Bellehumeur (19) observed that chronic infusion of NOS1 antisense oligonucleotides or the NOS1-specific inhibitor 7-nitroindazole resulted in chronic hypertension. More recently, Mattson and Meister (20) observed that NOS3 does not account for salt sensitivity in mice treated with the nonspecific NOS inhibitor L-NAME. These findings are consistent with an important role for one of the other NOS isoforms, such as NOS1, in determining salt sensitivity. The current study provides additional evidence to link the ET B receptor and NOS1 activity within the renal medulla in the control of sodium excretion. A seemingly contrasting observation to this overall hypothesis is that NOS1 knockout mice have normal blood pressures (21) . However, these mice only lack the NOS1␣ and may express other splice variants that could compensate. Furthermore, the NOS1␣ knockout mice have not been characterized in terms of their ability to excrete salt and water.
Considerable evidence has demonstrated an important role for ET B receptors in the regulation of blood pressure via control of renal sodium excretion. Our laboratory has previously shown that chronic blockade of ET B receptors results in hypertension that is salt dependent (44) . Likewise, Gariepy et al. (7) have shown that rats with a genetic mutation of the ET B receptor also display salt-dependent hypertension. A more specific role for ET-1 and ET B receptors within the collecting duct is derived from recent studies demonstrating that the tissue-specific deletion of ET-1 or ET B receptors from the collecting duct results in salt-dependent hypertension (1, 8) . The current study extends these findings although the precise mechanisms by which ET B receptors transmit signals to increase urine sodium and water excretion through NOS1, cGMP, and PKG will need to be elucidated in future studies.
Perspectives
A role for ET-1 and the renal ET B receptor in the long-term control of renal salt and water excretion now appears well established given results from genetic deletion studies as well as pharmacological experiments (1, 7, 8, 25) . Improvements in our understanding of the downstream signaling pathways for the renal ET B receptor will provide further insight into the specific role of the ET-1/ET B system in controlling excretory function. It is expected that the relationship among ET B , NOS, and urine excretion may change along with the development of renal-dependent disorders, such as salt-sensitive hypertension. We speculate that factors interfering with the ET-1/ET B signaling pathway could contribute to salt-induced elevations in blood pressure. In any event, our studies demonstrate an important link between ET B -dependent changes in sodium and water excretion in the renal medulla and the activity of NOS1, cGMP, and PKG in a normotensive rat.
